Head and Neck Squamous Cell Carcinoma - Pipeline Insights, 2016; New Report Launched

Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all 99 pipeline drugs that fall under the category of Head and Neck Squamous Cell Carcinoma. Eli Lilly’s Exbitux (Cetuximab) is the first monoclonal antibody for head and neck cancer.

The report provides a detailed insight of all the pipeline drugs. Keytruda (Pembrolizumab) of Merck is one of the most promising drug candidates. Pipeline for Head and Neck cancer looks strong as many companies are coming up with the biosimilar versions of cetuximab like R-Pharm and Sorrento. Researchers are working to get next-generation treatments like antibody-drug conjugates or immunotherapy, which might yield better results than chemotherapy alone.

The report also provides a comparative analysis of therapeutics based on the molecule type, route of administration, etc. It also gives insights of other activities such as, agreements, joint ventures, partnerships, acquisitions and mergers.

Scope:

• The report, provides a Head and Neck Squamous Cell Carcinoma Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
• Coverage of the Head and Neck Squamous Cell Carcinoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Head and Neck Squamous Cell Carcinoma and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Reasons to Buy

• Complete Pipeline intelligence and complete understanding over therapeutics development for Head And Neck Cancer Squamous Cell Carcinoma
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Spanning over 338 pages, “Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016” report covers Head and Neck Squamous Cell Carcinoma Overview, Epidemiology, Market Scenario, Market Barriers, Market Drivers, Comparative Analysis, Therapeutic Assessment, Appendix.

For more information Visit at: http://mrr.cm/oCJ

Find all Drug Discovery Reports at: http://www.marketresearchreports.com/drug-discovery